Applications Invited for Promotion of Research and Innovation in Pharma MedTech sector (PRIP) Scheme

Follow us@ngobox

About the Organization

The Department of Pharmaceuticals was created on the 1st of July in the year 2008 in the Ministry of Chemicals & Fertilizers with the objective to give greater focus and thrust on the development of pharmaceutical sector in the country and to regulate various complex issues related to pricing and availability of medicines at affordable prices, research & development, protection of intellectual property rights and international commitments related to pharmaceutical sector which required integration of work with other Ministries.

Vision: To make India the Largest Global Provider of Quality Medicines at Reasonable Prices.

Mission: Ensure availability of quality drugs at reasonable prices as per the Pharma Policy.Promote Pharma Brand India. Encourage environmentally sustainable development of Pharmaceutical IndustryTo establish NIPERs as nationally and internationally recognized brand in the field of education and research of pharmaceutical sciences for the benefit of human kind.

About the Grant

The Scheme for "Promotion of Research and Innovation in Pharma MedTech sector (PRIP)" has been launched by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, with the goal of transforming India into a global powerhouse for R&D in the Pharma MedTech sector. The scheme has a total financial outlay of ₹5000 crores, which includes ₹700 crores to establish Centers of Excellence (CoEs) at seven National Institutes of Pharmaceutical Education & Research (NIPERs), and ₹4200 crores to accelerate investments in the R&D ecosystem within the sector.

• Enable rapid discovery, development and commercialization of drugs
• Enable innovation in medical devices
• Promote industry-academia collaboration
• Transform from cost based to innovation driven growth

Objectives:

The objective of the scheme is to transform Indian Pharma MedTech sector from cost based to innovation-based growth by strengthening the research infrastructure in the country. The aim of the scheme is to promote industry-academia linkage for R&D in priority areas and to inculcate the culture of quality research and nurture our pool of scientists. This will lead to sustained global competitive advantage and contribute to quality employment generation in the country.

Scheme Categories:

Academic collaboration open for projects in both the categories:

Early Stage Projects

• Open for Startups and MSMEs only
• Technology Readiness Levels (TRL)
• Projects having completed TRL 1, 2 or 3 to reach higher TRLs up to 5
• Financial assistance:
• Up to ₹1Cr, fully funded
• Beyond ₹1Cr up to 5Cr, assistance up to 50% of project cost

Later Stage Projects

• Technology Readiness Levels (TRL)
• Projects having completed TRL 4, 5 or 6 to reach higher TRLs
• Financial assistance:
• Up to ₹100Cr, assistance up to 35% of project cost
• For Strategic Priority Innovations, assistance up to 50%

Priority Areas:

• New Medicines
• New Chemical medicines/substances (including new chemical entities): Drug not previously approved for safety and efficacy in India
• New Biological Entities: Biological product not previously approved for safety and efficacy in India (incl. gene and stem cell therapy)
• Phytopharmaceutical drugs: This refers to medicines not previously approved as safe and efficacious by the licensing authority in India. Such new medicines also include APIs, and Ayurvedic, Siddha, Unani, Sowa-Rigpa, and Homoeopathic medicines.
• Complex generics & Biosimilars
• Complex Generics: Previously approved by CDSCO for certain claims, proposed with modified or new claims e.g., indication, route of administration, dosage, dosage form or a novel drug -delivery system.
• Biosimilars: Biological product similar in quality, safety and efficacy to a licensed reference product in India or an innovator product approved in an ICH member country
• Novel Medical Devices
• New devices not previously approved by CDSCO, such as:
• AI/ML-based, Software as Medical device(SaMD) and Software in Medical Device(SiMD)
• Diagnostics and screening devices using genetic technologies
• Robotic devices for surgical procedures
• Devices with telemedicine capabilities
• Novel in-vitro diagnostics (IVDs), including biomarker-based tests for precision medicine
• Non Exhaustive

Highlights:

Support Strategic Priority Innovations

• Promote innovative products and technologies that address areas of India's public health concern for which market potential is relatively lower
• Diseases referred to as Neglected Tropical Diseases relevant to India
• Rare diseases in India
• Antimicrobial resistance for India Priority Pathogens
• Priority pathogens that cause outbreaks or pandemics
• Vaccines for vaccine-preventable diseases
• Other diseases, pathogens or vaccines as DHR, MoHFW may specify for purposes of this policy

Promote Academic Collaboration

• Encourage industry and startups to collaborate with reputed Government academic and research institutions (“Academia”) for both Early Stage and Later Stage Projects.
• Preference given to up to nine projects from each category involving significant collaborative development with Academia (subject to quality of proposals and credentials of collaborative partners/team).
• Costs of project linked in-licensing or tech transfer considered eligible for assistance
• Capital expenditure on project linked infrastructure / equipment transferred to the Academia exempted at the time of benefit -share calculation

How to Apply

Funding Process:

• Call for Applications Live Now
• Technical Evaluation
• Approval for Financial Assistance
• Disbursement & Monitoring

Deadline to Register on PRIP Portal: 3rd November 2025, 11:59 PM

For more information please check the Link

Stay in the loop with the newest RFPs and Grants through NGOBOX's WhatsApp Channel. Join now by clicking here!

Tags Healthcare and Healthtech Research Others